About Imipenem-Cilastatin Dosing

The Imipenem-Cilastatin Dose Calculator provides dosing recommendations for this broad-spectrum carbapenem antibiotic based on patient-specific renal function. Imipenem is primarily cleared by the kidneys, making it essential to adjust the dosing schedule in patients with renal impairment. Cilastatin is co-administered to inhibit the renal enzyme dehydropeptidase-I, which prevents the metabolism of imipenem and increases its urinary concentration. Accurate dose adjustments are critical to maintain therapeutic efficacy while minimizing the risk of adverse effects, most notably seizures.

Calculator Outputs Explained

Upon entering the required patient data, the calculator provides the following key outputs for intravenous (IV) administration:

• Recommended Dose: The specific amount of imipenem-cilastatin (in mg) to be administered per dose.
• Dosing Frequency: The recommended interval between doses (e.g., every 6, 8, or 12 hours).
• Creatinine Clearance (CrCl): Displays the CrCl value used for the calculation, either calculated via the Cockcroft-Gault equation or the value entered manually.
• Dosing Rationale: A brief explanation of why the specific dose was recommended, typically based on the level of renal function (e.g., normal, mild, moderate, or severe impairment).
• Safety Information: Important alerts, such as the increased risk of seizures in patients with compromised renal function or pre-existing CNS disorders.

How to Use the Calculator

Follow these steps to determine the appropriate imipenem-cilastatin dose:

1. Select Input Method: Choose whether to have the tool calculate Creatinine Clearance (CrCl) or to enter a known CrCl value manually.
2. Enter Patient Data: If calculating CrCl, provide the patient's age (in years), weight (in kg or lbs), sex, and serum creatinine (in mg/dL or µmol/L). If entering manually, provide the CrCl value in mL/min.
3. Select Indication Severity: Choose between "Mild-to-Moderate Infection" and "Severe Infection / Pseudomonas aeruginosa" as this can affect the target dose.
4. Calculate and Review: Click the "Calculate Dose" button to generate the dosing recommendation. Carefully review all outputs before clinical application.

Dosing Overview

The following table summarizes typical intravenous dosing adjustments for adults with a body weight of 70 kg or less, based on creatinine clearance (CrCl). Dosing for patients over 70 kg should be based on the 70 kg weight dose unless the benefits outweigh the risks. Always consult the full prescribing information.

Switching Therapy

Imipenem-cilastatin is only available as an intravenous formulation. When a patient's condition improves, a healthcare provider may decide to switch from IV administration to a suitable oral antibiotic. This "step-down" therapy is a clinical decision based on the patient's stability, the causative pathogen's susceptibility, and the availability of an appropriate oral agent. This tool does not provide recommendations for switching to other antibiotics.

Missed Dose Protocol

Since imipenem-cilastatin is administered by healthcare professionals in a clinical setting, a missed dose is uncommon. If a dose is delayed, it should be given as soon as possible and the subsequent administration times adjusted to maintain the correct dosing interval. The schedule should be corrected to avoid administering two doses too close together. Do not double the dose to make up for a missed one.

Safety Alerts

• Hypersensitivity Reactions: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported. Before initiating therapy, inquire about previous hypersensitivity reactions to carbapenems, penicillins, cephalosporins, or other beta-lactams.
• Clostridioides difficile-Associated Diarrhea (CDAD): CDAD has been reported with nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis.

Frequently Asked Questions

1. Why is renal function so important for imipenem-cilastatin dosing?
Imipenem is eliminated from the body primarily through the kidneys. In patients with impaired renal function, the drug can accumulate to toxic levels, significantly increasing the risk of adverse effects like seizures. Dose adjustment based on creatinine clearance is mandatory.

2. What is cilastatin and why is it combined with imipenem?
Cilastatin is a renal dehydropeptidase inhibitor. It has no antibacterial activity but prevents the breakdown of imipenem by an enzyme in the kidneys. This increases the concentration of active imipenem in the urinary tract and reduces potential renal toxicity.

3. Should I use Actual, Ideal, or Adjusted Body Weight for the calculation?
The Cockcroft-Gault equation was originally developed using actual body weight. The tool's tooltip advises using Actual Body Weight but recommends exercising clinical judgment for obese patients, where using an adjusted body weight might be more appropriate to avoid overestimation of renal function.

4. What happens if the calculated CrCl is less than 10 mL/min?
The calculator indicates that imipenem-cilastatin is not recommended for this population. These patients have severe renal failure and require specialist management. Dosing in this population, including those on hemodialysis, is complex and falls outside the scope of this standard calculator.

5. Can this calculator be used for pediatric patients?
No. This calculator is designed for adult patients only (age ≥ 18 years). Pediatric dosing is different and often based on weight (mg/kg) and age-specific factors.

6. How is the IV infusion administered?
The dose is typically infused intravenously over a period of 20 to 60 minutes, depending on the dose size. Doses ≤ 500 mg are often infused over 20-30 minutes, while larger doses (e.g., 1 gram) are infused over 40-60 minutes.

7. Why does the calculator use the Cockcroft-Gault equation?
The Cockcroft-Gault equation is the formula historically used in clinical trials to establish the renal-impaired dosing regimens for many drugs, including imipenem-cilastatin. The official prescribing information bases its recommendations on CrCl levels derived from this equation.

8. What does the "Indication (Severity)" option change in the calculation?
This option adjusts the target dose. Severe infections, particularly those caused by less susceptible organisms like Pseudomonas aeruginosa, may require higher doses (e.g., 1 gram) in patients with normal renal function. The subsequent renal adjustments are then based on this higher initial dose.

References

1. PRIMAXIN® I.V. (Imipenem and Cilastatin for Injection) Prescribing Information. U.S. Food and Drug Administration. Revised: March 2012.
2. DailyMed - Imipenem and Cilastatin for Injection Label. U.S. National Library of Medicine.
3. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41. doi:10.1159/000180580
4. Pestotnik SL, Classen DC, Evans RS, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1996;275(4):305-307. (General reference on importance of correct dosing).